



**Supplementary Figure 1 uPAR and CTCs.** A: There was a similar proportion of uPAR positive CTCs in patients with localised and metastatic disease (mean proportion uPAR positive CTCs 48.8% vs 47.7% respectively,  $p=0.89$ ); B: Patients with >50% CTCs positive for uPAR had a similar overall survival compared to those with  $\leq 50\%$  uPAR positive CTCs (median OS 12.8 vs 17.0 months,  $p=0.60$ ).